4P-Pharma, a biotechnology company specialised in the sourcing and the development of early stage therapeutic molecules, announced the appointment of Sonia Escaich, PhD, as Chief Operating Officer.
“Sonia has deep domain expertise from both drug development and business perspective, she will bring a wealth of experience to the team”, said Revital Rattenbach, Founder and President of 4P-Pharma. “[…] I have full confidence that she will help accelerate our scientific programs development and operational efficiencies that will take 4P-Pharma to the next level.”
“[…] This is indeed a great time for 4P-Pharma and I look forward to [Sonia’s] strong professional support to all of our R&D operations as well as funding opportunities”, added Dr. Patrice Denèfle, Chief Scientific Officer of 4P-Pharma.
“[…] I am delighted to join 4P-Pharma dynamic team, and to participate to the development of its therapeutic innovations in fields with high medical needs.”, said Dr. Sonia Escaich.
4P-Pharma, a biotechnology company specialised in the sourcing and the development of early stage therapeutic molecules, announces the appointment of Patrice Denèfle, PhD, HDR, Adjunct Prof., as its Chief Scientific Officer (CSO).
“We are delighted to welcome Patrice to our team as Chief Scientific Officer. […] I look forward to work closely with him to push forward 4P-Pharma’s strong momentum”, said Revital Rattenbach, Founder and President of 4P-Pharma.
“I am thrilled to join 4P-Pharma team as CSO, as the company has a very impressive record of innovative projects. […] I am looking forward to work with all the team of 4P-Pharma and its scientific and advisory board to support and boost the clinical development of 4P004 and bring my expertise to expand 4P-Pharma’s portfolio drug candidates”, said Patrice Denèfle.
4P-Pharma received the Seal of Excellence from the European Commission for its application related to the development of a disease modifier treatment for osteoarthritis, 4P-004 to the Horizon 2020 EIC Accelerator (SME instrument).
Following evaluation by an international panel of independent experts, 4P-Pharma’s project was scored as a high-quality proposal in this highly competitive evaluation process, passing all their stringent assessment thresholds for the 3 award criteria (i.e. excellence, impact and implementation).
A poster on 4P-004 entitled “Protective Effects Of Intra-Articular Formulated Liraglutide In Osteoarthritis” (#1970) will be presented during the 2nd Therapeutic Discoveries from Bench to First in Human Clinical Trials Conference, in Riyadh, Saudi Arabia, February 25th -27th, 2020.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
4P-Pharma appoints Sonia Escaich as Chief Operating Officer
4P-Pharma, a biotechnology company specialised in the sourcing and the development of early stage therapeutic molecules, announced the appointment of Sonia Escaich, PhD, as Chief Operating Officer.
Sonia Escaich, Chief Operating Officer
Read the full press release
English version: PR_4P-Pharma_Escaich_vEN
French version: CP_4P-Pharma_Escaich_vFR
4P-Pharma press contact
Roselina Lam, Business development and Licensing Manager
Phone: +33 (0)9 50 72 97 68 – E-mail: roselina@4p-pharma.com
4P-Pharma appoints Patrice Denèfle as Chief Scientific Officer
4P-Pharma, a biotechnology company specialised in the sourcing and the development of early stage therapeutic molecules, announces the appointment of Patrice Denèfle, PhD, HDR, Adjunct Prof., as its Chief Scientific Officer (CSO).
Patrice Denèfle, Chief Scientific Officer
Read the full press release
English version: 202005_PR_4P-Pharma_Denefle_vEN
French version: 202005_PR_4P-Pharma_Denefle_vFR
4P-Pharma press contact
Roselina Lam, Business development and Licensing Manager
Phone: +33 (0)9 50 72 97 68 – E-mail: roselina@4p-pharma.com
4P-Pharma at BIO Europe Spring 2020
Roselina Lam, our Business Development and Licensing Manager, will attend the upcoming BIO Europe Spring on March 23rd-25th, 2020 in Paris, France.
Contact her via the partnering platform or by e-mail, to learn more about our pipeline and discuss future partnerships.
She is looking forward to meet you there!
4P-Pharma received the Seal of Excellence from the European Commission
4P-Pharma received the Seal of Excellence from the European Commission for its application related to the development of a disease modifier treatment for osteoarthritis, 4P-004 to the Horizon 2020 EIC Accelerator (SME instrument).
Following evaluation by an international panel of independent experts, 4P-Pharma’s project was scored as a high-quality proposal in this highly competitive evaluation process, passing all their stringent assessment thresholds for the 3 award criteria (i.e. excellence, impact and implementation).
4P-Pharma will present 4P-004 at the 2nd Therapeutic Discoveries Conference in Riyadh, Saudi Arabia
A poster on 4P-004 entitled “Protective Effects Of Intra-Articular Formulated Liraglutide In Osteoarthritis” (#1970) will be presented during the 2nd Therapeutic Discoveries from Bench to First in Human Clinical Trials Conference, in Riyadh, Saudi Arabia, February 25th -27th, 2020.